Evan Wu, MD, PhD

Experts explain racial gaps in molecular testing and how limited trial diversity affects treating HER2-mutant lung cancer in Black patients.

Compare oral vs IV HER2-targeted lung cancer therapies, including zangertinib and antibody–drug conjugates, with response rates and access considerations.

Learn how zangontinib affects statins and liver risk, when to switch to pravastatin, and how to monitor labs remotely for hepatitis B safety.

Learn how zangontinib affects atorvastatin, raises liver-risk, and why frequent LFTs plus entecavir may prevent hepatitis B reactivation.

NCCN guidance highlights how HER2-mutant lung cancer may still benefit from chemo‑immunotherapy, as PD‑L1 and response patterns differ from EGFR/ALK/RET/ROS1.

Limited lung cancer tissue? Pair liquid biopsy with NGS to spot actionable mutations fast and choose targeted therapy without delaying care.

Explore first-line therapy for HER2-mutated advanced NSCLC in an older patient, covering biomarker testing, liquid biopsy timing, and tailored HER2-targeted options.